Global vs Local Governance Rules


Global vs Local Governance Rules

Published on 02/12/2025

Global vs Local Governance Rules: A Step-by-Step Guide to AI/ML Model Validation in GxP Analytics

In the evolving landscape of the pharmaceutical industry, artificial intelligence (AI) and machine learning (ML) are becoming increasingly integrated into Good Practice (GxP) analytics. As organizations implement these technologies, they must navigate the complexities of governance and security to comply with both local and global regulations. This article presents a detailed, step-by-step tutorial on the governance of AI/ML model validation, focusing on crucial elements such as intended use risk, data readiness curation, bias and fairness testing, and model verification and validation.

Understanding the Regulatory Landscape for AI/ML in Pharma

The implementation of AI/ML technologies in the pharmaceutical sector is subject to various global and local regulations. Regulatory bodies such as the FDA, EMA, MHRA, and guidelines provided by organizations like ICH and PIC/S have set forth specific requirements that must be adhered to.

In the United States, for instance, adherence to regulations such as 21 CFR Part 11 is required for electronic records and signatures. This regulation outlines the criteria under which electronic records and signatures are considered trustworthy, reliable, and equivalent to paper records. In the EU, Annex 11 to the EU GMP guidelines specifically addresses computerized systems, setting standards for the management of data integrity and system validation.

Furthermore, the use of AI in GxP analytics raises questions regarding risk management. Organizations must consider the intended use of AI/ML models, the data inputs, and the potential risks associated with their deployment. Therefore, establishing a governance framework that encompasses both global and local compliance is critical.

Step 1: Establishing Governance Frameworks for AI/ML

Creating a comprehensive governance framework is the first step in ensuring compliance with regulatory standards for AI/ML models in a pharmaceutical context. This framework should include policies and procedures that define roles and responsibilities, processes for model development, and guidelines for risk management.

  • Define Roles and Responsibilities: Establish a governance committee comprising diverse stakeholders, including regulatory affairs, quality assurance, IT, and clinical operations. This committee will be responsible for overseeing compliance and ensuring the integrity of AI/ML models.
  • Develop Policies and Procedures: Create documentation outlining procedures related to model development, validation, monitoring, and re-validation. Reference industry standards such as GAMP 5, which provides guidance on the validation of automated systems.
  • Implement Risk Management Practices: Conduct a thorough risk assessment to identify potential risks associated with AI/ML technologies. Classify risks according to their severity and likelihood, and develop mitigation strategies for each identified risk.

Compliance with regional regulations must be maintained while seeking to standardize processes across jurisdictions where applicable. This delicate balance ensures that both global and local governance requirements are met.

Step 2: Intended Use and Data Readiness Curation

Once the governance frameworks are established, the next step involves defining the intended use of AI/ML models and ensuring data readiness. The intended use encompasses the purpose for which a model will be developed and deployed, which directly influences how the model is validated and monitored.

  • Define Intended Use: Clearly articulate the scope and objectives of the AI/ML model. This includes specifying the clinical or operational goals, as well as the decisions that the model will inform or support. Understanding the intended use will guide subsequent validation processes.
  • Data Readiness Curation: Evaluate the quality, relevance, and completeness of the data that will be used to train and test the AI/ML models. This involves curating datasets to ensure they are representative of the intended use cases and free from biases that could skew results.
  • Documentation: Maintain comprehensive documentation of data sources, selection criteria, and any preprocessing steps taken during data curation. This ensures traceability and compliance with regulatory expectations regarding data integrity.

Regulatory authorities often emphasize the importance of data governance in their guidelines. Ensuring data readiness before diving into model validation cannot be stressed enough, as incorrect or poor-quality data can compromise results.

Step 3: Bias and Fairness Testing in AI/ML Models

One of the pivotal elements of AI/ML model validation is conducting bias and fairness testing. Bias can arise from various sources, including data collection methods, feature selection, and algorithm design. Addressing biases is essential to foster fairness and ensure that models do not inadvertently harm certain groups or lead to unequal healthcare outcomes.

  • Conduct Preliminary Bias Assessments: Use statistical methods to assess whether the models perform uniformly across different demographic groups. Analyze performance metrics across various subgroups, ensuring that no group is disproportionately affected.
  • Implement Fairness Testing Methods: Employ advanced algorithms designed to mitigate biases, such as re-weighting, adversarial training, or fairness constraints. Choosing the right method depends on the nature of the model and the specific biases identified.
  • Document Testing Results: All bias testing efforts must be thoroughly documented, including the methods used, the results obtained, and any corrective actions taken. This documentation serves as an audit trail during inspections or audits.

By proactively addressing bias, organizations can enhance the credibility and acceptance of their AI/ML models, ensuring that they align with ethical standards and regulatory expectations.

Step 4: Model Verification and Validation Practices

Model verification and validation (V&V) are critical to ensure that AI/ML models function as intended and produce reliable outcomes. The V&V processes confirm that the models not only meet regulatory standards but also perform reliably under various conditions.

  • Verification Phase: Engage in activities that ensure the model was built correctly according to the defined specifications. This involves system and code checks, evaluating whether the model was designed according to the governance framework established previously.
  • Validation Phase: Validation is performed to confirm that the model meets its intended use based on the training and test datasets. This phase often involves conducting performance evaluations using additional datasets not used in training. Metrics such as accuracy, specificity, sensitivity, and clinical relevance are assessed here.
  • Ongoing V&V Procedures: Once validated, the model must undergo periodic re-validation to ensure continued compliance and optimal performance. Establish drift monitoring mechanisms to track any deviations or changes in the model’s performance over time.

Adhering to a robust V&V process is fundamental in building trust in AI/ML technologies, enabling organizations to confidently implement these models in their operations.

Step 5: Explainability, Drift Monitoring, and Re-Validation

As regulatory bodies increasingly emphasize the importance of model transparency and accountability, explainability (XAI) becomes a crucial aspect of AI/ML in pharma. Demonstrating how models arrive at their conclusions is essential not only for regulatory compliance but also for ethical practices.

  • Implement Explainability Techniques: Leverage XAI frameworks and techniques, such as LIME or SHAP (SHapley Additive exPlanations), to elucidate the reasoning behind model predictions. Providing stakeholders with insights into model decisions enhances trust and facilitates regulatory reviews.
  • Establish Drift Monitoring: Continuous monitoring of model performance is vital to identify any function drift that may occur due to changes in data distribution or underlying conditions. Set thresholds for acceptable performance metrics, triggering reviews if dips in performance are noted.
  • Regular Re-Validation: Based on monitoring outcomes, implement re-validation schedules as part of the governance framework. This should coincide with significant changes in data, model updates, or shifts in intended use.

These steps underscore the importance of maintaining a high level of accountability in AI/ML development and deployment, ensuring that all stakeholder interests are considered and regulatory compliance is achieved.

Step 6: Documentation and Audit Trails

Proper documentation and maintenance of audit trails are essential components of AI/ML model governance. Regulatory authorities require comprehensive records to demonstrate compliance and provide insights into model development, validation, and maintenance processes.

  • Maintain Comprehensive Documentation: Document every aspect of the model’s lifecycle, including governance frameworks, defined roles, data curation efforts, testing protocols, verification, validation outcomes, and monitoring results. This documentation should be accessible and organized systematically.
  • Establish Audit Trails: Implement systems for logging all changes and updates made to the model and the data it processes. Ensure that these logs capture sufficient detail to facilitate audits and reviews. Implement regular audits to assess compliance with established governance standards.
  • Training and Capacity Building: Continuous training for personnel involved in AI/ML model governance is essential in keeping the team informed of the latest regulatory expectations, best practices, and technological advancements.

Robust documentation practices are instrumental in establishing accountability and reliability in AI/ML executions, simplifying the audit process for regulatory agencies.

Conclusion: Embracing Global and Local Governance for AI/ML in Pharma

As the integration of AI and ML technologies into pharmaceutical analytics continues to grow, the importance of establishing structured, compliant governance frameworks cannot be overstated. This article has outlined a step-by-step tutorial to facilitate understanding and implementation of the necessary validation practices relating to AI/ML models, focusing on intended use, data readiness, bias testing, model verification, explainability, and documentation.

By embracing both global and local governance rules, pharmaceutical organizations can ensure that their AI/ML systems align with regulatory expectations, offering substantial benefits to clinical operations and improving overall patient care. A thorough understanding of these frameworks not only mitigates risks but also positions organizations to fully leverage the transformative potential of AI in the pharmaceutical landscape.